Physical activity is associated with better global cognition and frontal function in overweight/obese older adults with metabolic syndrome

Nina Coll-Padrós 1, María León 1, Natalia Valech 1, Emilio Ros 2,3, Josep Vidal 4,5, Ramon Estruch 3,6, Montserrat Fitó 3,7, Jordi Salas-Salvadó 3,8, Dolores Corella 3,9, José Luis Molinuevo 1,10 and Lorena Rami 1*

Abstract

Background: There is epidemiological evidence of an association between the metabolic syndrome (MetS), a cluster of cardiovascular risk factors related to central adiposity and insulin resistance, and cognitive impairment and dementia. On the other hand, there is evidence for a beneficial effect of physical activity on cognitive outcomes in older adult populations. In a cross-sectional study, we evaluated the relationship between aerobic physical activity and cognition in a cohort of overweight/obese older adults with MetS at risk for dementia. Cognitive function was assessed in a subsample of 82 subjects (men 55–75 y; women 60–75 y), with MetS and a BMI ≥ 27 to < 40 kg/m² enrolled in the PREDIMED-PLUS study, a trial of diet and exercise in individuals with MetS with outcomes of cardiovascular prevention. Domain Z scores were calculated for the different cognitive domains. Aerobic physical activity was determined with the Rapid Assessment of Physical Activity questionnaire.

Results: Adjusted covariance analyses revealed that, compared to sedentary participants, those physically active obtained higher scores in mean global cognitive scores, with mean adjusted difference 0.254 (95% CI 0.032 to 0.477, \(p = 0.026\)) and frontal composites, with mean adjusted difference 0.375 (95% CI 0.110 to 0.639, \(p = 0.006\)).

Conclusions: Our findings indicate that aerobic physical activity is associated with better global cognition and frontal function in overweight/obese older individuals with MetS, suggesting that physical activity could be a therapeutic strategy to reduce the risk of developing cognitive impairment or dementia in this population.

Keywords: Cognitive function, Physical activity, Aging, Metabolic syndrome, Obesity, PREDIMED-PLUS study

Background

In the last decades, the number of persons living with chronic age-related conditions, such as dementia, diabetes or hypertension, has enormously grown as a consequence of the increased life expectancy and the global aging of the population, and these population changes are already having a considerable impact on social and public health systems [1].

The metabolic syndrome (MetS) refers to a cluster of cardiometabolic factors, including excess abdominal fat, high blood pressure, high blood sugar, high triglyceride levels and low HDL-cholesterol. Sedentary lifestyle habits and increasing obesity rates explain an epidemic growth of MetS prevalence worldwide. The available evidence indicates that presently close to 30% of the adult population worldwide harbours the MetS [2]. MetS prevalence is strongly related to age: by age 60, 46.7% of the U.S. population was affected [3]. The MetS has long been known to be associated with an increased risk of cardiovascular disease and type-2 diabetes; but in recent years evidence has accumulated that individuals with MetS are also at high risk for developing neurological conditions such as cognitive impairment and dementia [4–6].
Despite that many studies have reported an association between MetS and poor cognitive function [7–13], controversy still exists. For example, a recent systematic review and meta-analysis of 13 longitudinal population-based studies found a weak association of MetS with cognitive decline, but this relationship was not observed in the older age group (> 70 years) when an age-stratified analysis was performed [14], concurring with other reports suggesting that the association between MetS and poor cognitive function does not hold in older populations [9, 15, 16]. In line with these findings, some studies indicate that the risk of developing dementia is stronger when exposure to risk factors such as obesity, diabetes or hypertension occurs in mid-life rather than in late life [17–19].

Similarly, the evidence for the effect of physical activity on cognition in older adults is still a topic under debate. While three meta-analyses of prospective studies found a positive effect of physical activity on cognition [20–22], another systematic review reported no cognitive benefit [23], and a recent large prospective cohort study with a 28-year follow-up suggested that physical activity in midlife is not associated with a reduced risk of dementia and that previous findings of a lower risk of dementia in physically active individuals might be attributable to reverse causation [24].

In recent years, increasing evidence shows that, compared to healthier individuals, those at an elevated risk of dementia are the ones who obtain greater health benefits from lifestyle interventions, therefore, preventive lifestyle interventions such as physical activity might result in better outcomes (e.g. significant cognitive improvement) when targeted to individuals who are at an increased risk of developing dementia (e.g. overweight/obese older adults with MetS) [25].

In this sense, it is worth noting that most epidemiological studies examining the effect of physical activity on cognitive outcomes have been carried out in populations of healthy older adults. Caution must be taken before generalizing study findings, as individuals with different risk profiles might obtain different results from similar lifestyle interventions.

The impact of physical activity on cognition in overweight/obese older individuals with MetS has not been studied. In fact, there are only a handful of studies on physical activity and cognition conducted in similar populations, e.g. patients with type-2 diabetes, insulin resistance or impaired glucose tolerance, but the evidence available so far does not seem to be robust enough to conclude that physical activity or exercise interventions contribute to a better cognitive performance in these patient groups [26].

In the present study we assessed the relationship between physical activity and cognition in a cohort of overweight/obese older adults with MetS at risk for dementia. We hypothesized that individuals who regularly engage in physical activity would perform better in a cognitive battery compared to individuals with no or very low physical activity.

**Methods**

**Study subjects**

This study is a cross-sectional analysis of baseline data acquired in a subsample of individuals enrolled in the PREDIMED-PLUS trial, a multicenter, randomized, parallel-group, clinical trial using a low-energy Mediterranean diet plus increased physical activity for the primary prevention of cardiovascular diseases (for more information, please refer to www.predimedplus.com). The local Ethics Committee approved the study and all participants provided written informed consent prior to enrolment.

Eligible candidates were community-dwelling men (aged 55 to 75 years) and women (aged 60 to 75 years) with overweight or obesity [body mass index (BMI) ≥27 to < 40 kg/m2] meeting at least three criteria for the MetS according to the updated harmonized criteria of the International Diabetes Federation and the American Heart Association and National Heart, Lung and Blood Institute [27]. Exclusion criteria were illiteracy, inability to provide written informed consent, history of any cardiovascular disease, active cancer or malignancy within the last 5 years, inability to follow the prescribed diet or attend study visits, participation in other weight loss programs in the 6 months before screening, history of surgery for weight loss, bowel resection or inflammatory bowel disease, obesity of endocrine origin, allergy to any food components of the Mediterranean diet, HIV, cirrhosis, alcohol abuse or addiction, serious psychiatric disorders, severe co-morbid condition with less than 24 months’ life expectancy, major organ transplantation, concurrent treatment with immunosuppressive drugs or systemic corticosteroids, or weight loss medication.

The sample for the present cognition study was identified through convenience sampling methods. Between February 2015 and December 2016 PREDIMED-Plus participants recruited in the 2 nodes based at Hospital Clinic were assessed for eligibility. Specific exclusion criteria for the cognition study were: Mini Mental State Examination (MMSE) < 26 [28]; obtaining abnormal scores (< 1.5 SD below the normative mean) on at least two of the neuropsychological tests performed; insufficient command of the Spanish language, having a serious/unstable neurological disease; taking psychoactive medication (benzodiazepines, opioids ...); history of significant head trauma or brain surgery; history of major depression or prior chemotherapy, and suffering
claustrophobia or having body implants incompatible with magnetic resonance imaging (MRI).

**Physical activity**

Physical activity was estimated with the Rapid Assessment of Physical Activity (RAPA) questionnaire [29], an easily administered tool for assessing level and intensity of physical activity among adults older than 50 years. The questionnaire has two sections: RAPA1 contains seven items measuring aerobic physical activities and RAPA2 contains two items measuring strength and flexibility. For the purpose of this study we focused solely on the RAPA1 (aerobic physical activity), with scores ranging from 1 (“I never do physical activity”) to 7 (“I do 75 minutes or more a week of vigorous physical activities”).

**APOE genotype**

Genomic DNA was extracted from buffy coat. We analyzed the common APOE polymorphism for all study participants on a 7900HT Sequence Detection System (Applied Biosystems, ABI; Foster City, CA, USA) by using fluorescent allelic discrimination TaqMan assays. Two APOE SNPs, rs429358 (Cys112Arg) and rs7412 (Arg158Cys), were selected for genotyping according to the NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP). The two APOE SNPs (call rate 99%) were further combined to derive the six APOE genotypes (ɛ2/ɛ2, ɛ2/ɛ3, ɛ3/ɛ3, ɛ3/ɛ4, ɛ4/ɛ4 and ɛ2/ɛ4). ɛ2/ɛ4, ɛ3/ɛ4 and ɛ4/ɛ4 were grouped as carriers of the ɛ4 allele (risk genotype) and so-called APOE4 carriers. Genotype frequencies did not deviate from Hardy-Weinberg equilibrium expectations.

**Neuropsychological assessment**

Participants underwent a complete neuropsychological assessment comprising all cognitive domains, which included the following tests: Rey Auditory Verbal Learning Test (RAVLT) [30], Rey-Osterrieth complex figure (ROCF) [31] copy and immediate recall, Semantic verbal fluency, Fragmented letters and Number location subtests of the Visual Object and Space Perception Battery [32], Trail Making Test (TMT) parts A & B [33], Symbol Digit Modalities Test (SDMT) [34], Stroop test [35] and WAIS IV digit span [36]. Depression symptomatology was collected with the Hospital Anxiety And Depression Scale (HADS) [37].

**Statistical analyses**

The characteristics of the two groups were compared by using Student’s t-test, Mann-Whitney or chi-square tests, as appropriate. We created domain composite cognitive measures by converting the individual test results to Z scores and computing the average Z scores within cognitive domains. The memory composite included the mean standardized individual scores of the RAVLT total learning and recall plus the recall of the ROCF. The frontal function composite included tests measuring attention, cognitive flexibility and working memory, and was built by averaging standardized scores of the TMT, SDMT, Stroop and WAIS IV digit span. The perception composite included the mean standardized individual scores of the VOSP fragmented letter and number location subtests. Language domain score included the standardized individual scores of the semantic fluency test and the praxis domain score included the standardized individual scores of the ROCF copy. Finally, a global cognition composite score was generated by computing the mean standardized scores of all measures.

Shapiro-Wilk normality test results indicated that Language, Praxis and Perception domain scores followed a non-normal distribution. For this reason, Language domain score was transformed into a logarithmic variable, and we confirmed that this transformation normalized data distribution. With regards to the Praxis and Perception domain scores, we determined it was not possible to make any valid conclusions with the data due to very limited variability (ceiling effects) and therefore those two scores could not be analysed.

Two groups were defined according to our sample RAPA1 aerobic physical activity median score: no or low physical activity (<3) vs. regular weekly physical activity of moderate to vigorous intensity (>3). We used covariance analyses to compare the global, memory, frontal function and language cognitive domain scores between the two groups: no or low physical activity vs. regular physical activity. Analyses were adjusted for Framingham risk score (encompassing sex, age, total cholesterol, HDL-cholesterol, systolic blood pressure and smoking status) [38] plus hypertriglyceridermia [defined as triglycerides > 150 mg/dL or fibrate treatment], diabetes [defined by clinical history and/or use of antidiabetic medication], BMI, education years, HADS depression score and presence of the APOE4 genotype. Abdominal obesity [waist circumference >= 102 cm in men; >= 88 cm in women] was not included as adjustment variable because 95.1% of the study sample had this MetS component. Statistical significance was set at the .05 level for all analyses, conducted with IBM SPSS software v. 22.

**Results**

For details of the flow of participants see Fig. 1. The study sample consisted of 82 individuals (51.2% women), mean age 66.8 ± 4.7 years and mean education 11.7 ± 4.2 years. The mean MMSE score was 29.11 ± 1.08 and mean BMI 32.0 ± 3.07 kg/m2. Regarding MetS components, 95.1% had abdominal obesity, 87.8% had hypertension, 56.1% had hypertriglyceridermia, 50.0% had low
Fig. 1 Flow of participants

452 individuals assessed for eligibility

92 not included
(Not meeting inclusion/exclusion criteria)

360 individuals included to PREDIMED-Plus & assessed for eligibility for the cognition study

142 not interested

218 formally screened for the cognition study

132 excluded
Declined to participate (n = 25)
Not meeting neuropsychological inclusion criteria (n = 40)
Other reasons (n = 67)
  ▪ Unwilling to undergo brain MRI, claustrophobia or incompatible body implants (n= 18)
  ▪ Lack of time or availability (n= 7)
  ▪ Impossible to reach or contact (n= 5)
  ▪ Taking psychoactive medication (n= 3)
  ▪ Insufficient command of Spanish language (n= 2)
  ▪ Other (n= 32)

86 included in the cognition study

4 excluded
(Missing data)

82 included in the analysis
HDL-cholesterol, and 65.9% had hyperglycemia or diabetes. In addition, 18.3% had a diagnosis of type-2 diabetes, 46.4% were either current or past smokers and 13.4% were APOE4 carriers. Participants were split into 59 with no or low physical activity and 23 with regular physical activity. The two groups were comparable in most characteristics, except for a higher proportion of women and of individuals with high blood pressure in the low physical activity group (Table 1).

Covariance analyses adjusted for Framingham risk score, hypertriglyceridemia, diabetes, BMI, education years, HADS depression score and APOE4 status revealed that physically active participants scored better in mean global and frontal cognitive composites compared to non-active participants. As shown in Table 2, differences in the global and the frontal composite scores were 0.254 (95% CI 0.032 to 0.477, \( p = 0.026 \)) and 0.375 (95% CI 0.110 to 0.639, \( p = 0.006 \)), respectively for physically active vs. non-active participants. No differences were observed in the memory or language cognitive domains. Adjusted results for single tests are presented in Table 3.

**Discussion**

The present results suggest that overweight/obese older adults with MetS at high risk for cardiovascular and neurological diseases who regularly engage in aerobic physical activity obtain higher scores in cognitive tests, independently of known cognition-related confounders (age, sex, BMI, educational level, diabetes, depression, APOE genotype) and cardiovascular risk factors. These findings are in line with most previous studies, which show that physical activity is beneficial for cognitive function in older adults [20, 21, 39, 40], although other studies have not found such an effect [23, 24]. Contrary to some previous reports on domain-specific benefits, we have not identified a significant association between physical activity and memory performance in our sample of overweight/obese older adults with MetS. Numerous studies have described attention and executive function as the cognitive domains most frequently affected by MetS in non-demented older adults [11, 41–44]. In this context, the fact that older adults with MetS who engage in regular weekly physical activity of moderate to vigorous intensity obtain better scores in frontal function tests compared to those with no or low physical activity levels is particularly relevant, and it could be argued that physical activity in these subjects helps maintain frontal function or counteracts the adverse effects of MetS on the cognitive areas commonly affected.

The biological mechanisms driving the harmful effects of MetS on cognition are not yet fully understood, but it is known that both cerebrovascular health [45] and structural integrity and connectivity of the brain [46] are compromised in individuals with MetS. Physical activity [47] and exercise [48–51] could exert beneficial effects on cognition in individuals with MetS by simultaneously improving cerebrovascular reserve (i.e., promoting angiogenesis, enhancing the capacity of brain blood vessels, increasing cerebral blood flow, improving oxygen and glucose delivery and modulating inflammation) and brain reserve (i.e., contributing to neurogenesis and synaptogenesis, improving the brain’s structural integrity, volume, plasticity and connectivity).

**Table 1** Subjects’ characteristics by physical activity level

|                          | No or low physical activity n = 59 | Regular physical activity n = 23 | \( P \) value* |
|--------------------------|-----------------------------------|----------------------------------|--------------|
| Sex (women)              | 59.3%                             | 30.4%                            | 0.028        |
| Age, years (mean, SD)    | 66.4 (4.68)                       | 67.8 (4.63)                      | 0.231        |
| Education, years (mean, SD) | 11.8 (4.37)                   | 11.7 (4.00)                      | 0.962        |
| MMSE (mean, SD)          | 29.1 (0.98)                       | 29.1 (3.13)                      | 0.661        |
| BMI, kg/m2 (mean, SD)    | 32.3 (3.12)                       | 31.2 (2.84)                      | 0.139        |
| Metabolic syndrome components: |                                 |                                  |              |
| Low HDL—cholesterol      | 45.8%                             | 60.9%                            | 0.219        |
| High triglycerides       | 55.9%                             | 56.5%                            | 0.961        |
| Abdominal obesity        | 96.6%                             | 91.3%                            | 0.316        |
| Hypertension             | 93.2%                             | 73.9%                            | 0.016        |
| Hyperglycaemia and diabetes | 69.5%                         | 56.5%                            | 0.614        |
| Sum of metabolic syndrome components | 3.61 (0.67)               | 3.39 (0.72)                      | 0.219        |
| Ever smoking             | 44.1%                             | 52.2%                            | 0.576        |
| APOE4 carriers           | 11.9%                             | 17.4%                            | 0.599        |
| Daily energy intake in kcal (mean, SD) | 2147.8 (532.07)               | 2303.06 (395.19)                 | 0.209        |

*Obtained by Student’s \( T \)-test, Mann—Whitney or Chi—quared test, as appropriate
In order to understand how physical activity might positively impact cognition, future studies should aim to unveil the cellular and molecular mechanisms that contribute to the maintenance of brain health focusing on older adults, and assess the interplay between markers of brain health, cognitive health and lifestyle factors (diet, physical activity, sleep quality, living environment, etc.) in aging populations, as this could potentially open the door to new preventative strategies or treatments for cognitive impairment.

At present, the global population is ageing and the incidence of age-related conditions is growing dramatically. As an example, the number of people living with dementia worldwide was estimated at 35.6 million in 2012, and is predicted to double by 2030 and more than triple by 2050 [1]. However this projection might be an overestimation since recent UK population cohort studies have reported a decrease of 1.8% in dementia prevalence [52] and a 20% drop in dementia incidence in the population aged 65 and above over two decades [53], thus suggesting that dementia prevalence will not increase and will remain relatively stable.

As a consequence of the longer lifespan and increasing numbers of older persons, the number of individuals requiring medical attention, social care and support to continue to live well independently will rise, placing additional pressure on national health care budgets and posing a direct threat to social and public health services [54]. In the context of global population ageing and the fact that obesity and MetS are epidemic at present in Western populations, the finding that overweight/obese older adults with MetS who practice regular physical activity obtain overall better cognitive scores compared to non-active individuals suggests that engaging in physical activity could be a useful strategy in preventing or delaying the onset of age-related cognitive impairment and dementia in a high risk population.

Strengths of our study include the use of a comprehensive battery of neuropsychological tests (as opposed to other studies relying solely on a single screening test, such as the MMSE) which allowed us to work with cognitive domain composite scores that are more robust and stable measures of cognitive performance, the focus on an understudied but increasingly prevalent population of older adults with overweight/obesity at high risk for developing chronic age-related conditions, and the inclusion of confounding variables in the analyses (such as education, APOE4 status and depressive symptomatology) that have been overlooked in other studies. We also acknowledge the limitations of our study, including

| Cognitive Domains     | No or low physical activity N = 59 | Regular physical activity N = 23 | Adjusted Difference | P value* |
|-----------------------|------------------------------------|---------------------------------|---------------------|---------|
| Global cognition      | −0.054 ± 0.53                      | 0.224 ± 0.61                   | 0.254 (0.032 to 0.477) | 0.026   |
| Frontal function      | −0.075 ± 0.62                      | 0.327 ± 0.70                   | 0.375 (0.110 to 0.639) | 0.006   |
| Memory                | −0.061 ± 0.78                      | 0.15 ± 0.79                    | 0.192 (−0.174 to 0.558) | 0.300   |
| Language              | 2.884 ± 0.25                       | 2.979 ± 0.25                   | 0.103 (−0.13 to 0.218) | 0.080   |

Data are means ± SD or adjusted means (95% CI)

*ANCOVA for group differences adjusted for Framingham risk score, diabetes, high triglycerides, BMI, education years, HADS depression score and APOE4

| Cognitive Test   | No or low physical activity N = 59 | Regular physical activity N = 23 | Adjusted Difference | P value* |
|------------------|------------------------------------|---------------------------------|---------------------|---------|
| TMT--A           | 41.10 ± 12.53                      | 38.35 ± 13.27                  | −1.504 (−7.800 to 4.791) | 0.635   |
| TMT--B           | 95.53 ± 31.63                      | 77.74 ± 24.88                  | 14.398 (−26.662 to −2.133) | 0.022   |
| SEMANTIC FLUENCY| 18.47 ± 4.99                       | 20.30 ± 5.53                   | 2.033 (−0.349 to 4.414) | 0.093   |
| RAVLT TOTAL      | 51.25 ± 9.14                       | 52.35 ± 8.14                   | 1.126 (−2.630 to 5.861) | 0.467   |
| ROCF COPY        | 33.30 ± 2.52                       | 33.52 ± 1.93                   | 0.185 (−1.013 to 1.382) | 0.759   |
| ROCF RECALL      | 18.11 ± 5.44                       | 20.68 ± 6.20                   | 2.555 (−1.501 to 4.401) | 0.567   |
| DIGIT SPAN DIRECT| 9.12 ± 2.32                        | 10.09 ± 2.50                   | 0.976 (−0.438 to 2.010) | 0.205   |
| DIGIT SPAN REVERSE| 5.86 ± 1.97                        | 6.74 ± 1.91                    | 0.971 (0.102 to 1.840) | 0.029   |
| VOSP LETTERS     | 19.51 ± 0.57                       | 19.48 ± 0.67                   | −0.041 (−0.332 to 0.251) | 0.782   |
| VOSP NUMBERS     | 8.92 ± 1.18                        | 8.91 ± 0.95                    | −0.010 (−0.064 to 0.443) | 0.716   |
| SDMT             | 40.02 ± 9.74                       | 46.78 ± 12.90                  | 6.182 (1.224 to 11.139) | 0.015   |
| STROOP           | 33.76 ± 8.60                       | 38.61 ± 8.97                   | 4.853 (1.156 to 9.449) | 0.013   |

Data are means ± SD or adjusted means (95% CI)

*ANCOVA for group differences adjusted for Framingham risk score, diabetes, high triglycerides, BMI, education years, HADS depression score and APOE4
its cross-sectional design, which does not permit to establish a cause-and-effect relationship, the small sample size and insufficient power to detect some effects, the lack of data on inflammatory biomarkers and the use of self-reported data on aerobic physical activity. Having objective physical activity measurements for all participants (e.g. accelerometer data) would have been preferable to avoid any possibility of misclassification bias, but it was not available.

**Conclusion**

The present findings support the hypothesis that overweight/obese older subjects with MetS who engage in regular physical activity perform better in a cognitive battery compared to individuals with no or very low physical activity. While our results are the derived from cross-sectional data and therefore do not allow for establishing causality, there is enough evidence in the literature to consider physical activity as a good therapeutic target for age-related cognitive decline risk modification due to its low cost, low risk and accessibility.

**Acknowledgements**

We thank Emili Corbella for providing statistical analysis advice and the PREDIMED-PLUS participants and personnel for their enthusiastic collaboration with this study. CIBEROBIN and CIBERDEM are initiatives of ISCIII, Spain.

**Authors’ contributions**

LR and JLM contributed conception and design of the study; LR also wrote the draft first of the manuscript. ER was involved in study design and writing of the manuscript. NCP was involved in planning, participant recruitment, data collection, database maintenance, data analysis and wrote the manuscript; ML recruited participants, collected data and maintained databases. NV was involved in planning, participant recruitment and data collection. RE and Jv provided access to participants recruited in their nodes. JSS coordinated the main trial; MF maintained databases and DC did blood sample analysis for APOE genotyping. All authors commented on the manuscript, read and approved the submitted version.

**Authors’ information**

Not applicable.

**Funding**

This study has been funded by Instituto de Salud Carlos III through the grant “PI14/000567”, co-funded by European Regional Development Fund/European Social Fund “Investing in your future”. LR is the recipient of a Miguel Servet grant from the Spanish Ministry of Science (CP2/00223) as senior investigator.

**Availability of data and materials**

There are restrictions on the availability of data for the PREDIMED-PLUS study, due to the signed consent agreements around data sharing, which only allow access to external researchers for research following the project purposes. Requestors wishing to access the PREDIMED-PLUS trial data used in this study can request to the corresponding author on reasonable request. The request will then be passed to members of the PREDIMED-PLUS Steering Committee for deliberation.

**Ethics approval and consent to participate**

All subjects have provided their written informed consent prior to enrolment, and the local Ethics Committee has approved the study protocol.

**Consent for publication**

Not applicable.

---

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Alzheimer’s Disease and Other Cognitive Disorders Unit, Neurology Service, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Carrer Villarreal 170, 08036 Barcelona, Spain. 2. Lipid Clinic, Department of Endocrinology and Nutrition, IDIBAPS, Hospital Clinic, Barcelona, Spain. 3. CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBIN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. 4. Department of Endocrinology and Nutrition, IDIBAPS, Hospital Clinic, Barcelona, Spain. 5. CIBER Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), ISCIII, Madrid, Spain. 6. Department of Internal Medicine, IDIBAPS, Hospital Clinic, Barcelona, Spain. 7. Cardiovascular Risk and Nutrition Research Group, IMIM-Institut de Recerca del Hospital del Mar, Barcelona, Spain. 8. Human Nutrition Unit, University Hospital of Sant Joan de Reus, Department of Biochemistry and Biotechnology, Pere Virgili Institute for Health Research, Reusia i Virgili University, Reus, Spain. 9. Genetic and Molecular Epidemiology Unit, School of Medicine, University of Valencia, Valencia, Spain. 10. Barcelona Beta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain.

**Received: 1 April 2019 Accepted: 21 October 2019**

**Published online: 06 December 2019**

**References**

1. World Health Organization and Alzheimer’s Disease International. Dementia: a public health priority. 2012.
2. Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 2017;960:1–17.
3. Aguilar M, Shukut T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 2015;313(19):1973.
4. Kim B, Feldman E. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp Mol Med. 2015;47:e149. https://doi.org/10.1038/emm.2015.3.
5. Raffaitin C, Gin H, Empana J-P, Helmer C, Barr C, Tzourio C, et al. Metabolic syndrome and risk for incident Alzheimer’s disease or vascular dementia: the Three-City study. Diabetes Care. 2009;32(1):169–74.
6. Frisardi V, Solfirizi V, Seripa D, Capurso C, Santamato A, Sancarlo D, et al. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer’s disease. Ageing Res Rev. 2010;9(4):399–417.
7. Solfirizi V, Scalfaro E, Capurso C, D’Introno A, Colacico AM, Frisardi V, et al. Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian longitudinal study on aging. Neurobiol Aging. 2011;32(11):1932–41.
8. Yaffe K, Haan M, Blackwell T, Cherkasova E, Whitmer RA, West N. Metabolic syndrome and cognitive decline in elderly Latinos: findings from the Sacramento area Latino study of aging study. J Am Geriatr Soc. 2007;55(5):738–62.
9. Katsumata Y, Todoroki H, Higashiusato Y, Yasura S, Willcox DC, Ohy S, et al. Metabolic syndrome and cognitive decline among the oldest old in Okinawa: in search of a mechanism. The KOCOA project. J Gerontol A Biol Sci Med Sci. 2012;67(2):126–34.
10. Yaffe K, Lindquist K, Kluse M, Cawthon R, Harris T, Hsueh WC, et al. Telomere length and cognitive function in community-dwelling elders: findings from the health ABC study. Neurobiol Aging. 2011;32(11):2055–60.
11. Dík MG, Jonker C, Comijs HC, Deeg DHJ, Kok A, Yaffe K, et al. Contribution of Metabolic Syndrome Components to Cognition in Older Individuals. Diabetes Care. 2007;30(10):2655–60. https://doi.org/10.2339/dc06-1190.
12. Crichton GE, Elias MF, Buckley JD, Murphy KJ, Bryan J, Frisardi V. Metabolic syndrome, cognitive performance, and dementia. J Alzheimers Dis. 2012;30(SUPPL 2):S77–87.
13. Visco Logisi G, Andreozzi P, Chiriac IM, Cipriani E, Servello A, Ettorre E, et al. Screening cognition in the elderly with metabolic syndrome. Metab Syndr Relat Disord. 2012;10(5):358–62.
14. Servo M, Harrison SL, Jagger C, Robinson L, Stephan BCM. Metabolic syndrome and longitudinal changes in cognitive function: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41(1):151–61.
15. Harrison SL, Stephan BCM, Servo M, Granc A, Davies K, Wesner KA, et al. Is there an association between metabolic syndrome and cognitive function in very old adults? The Newcastle 85+ study. J Am Geriatr Soc. 2015;63(4):667–75.
16. Laudisio A, Marzetti E, Pagano F, Cocchi A, Franceschi C, Bernabei R, et al. Association of metabolic syndrome with cognitive function: the role of sex and age. Clin Nutr. 2008;27:747–54.
